The decision between coronary artery bypass grafting (CABG) vs. percutaneous coronary intervention (PCI) in a patient with complex (left main and multivessel) coronary artery disease (CAD) requiring revascularization can be a difficult one. Patients together with their doctors want to choose the least morbid procedure that gives the best longterm outcome. Contemporary comparative studies in patients with complex CAD consistently show that while PCI is less morbid (less procedural stroke and adverse events), CABG generally is more efficacious, clearly reducing repeat revascularization for most patients, as well as death and myocardial infarction (MI) for many. [1] [2] [3] [4] [5] What is not
clear is at what level of CAD complexity do CABG outcomes surpass PCI outcomes, particularly with regards to safety. This is particularly important for patients with diabetes, 20-40% of the complex CAD population, who have a higher burden of atherosclerosis ('diffuse disease'), worse prognoses, and, historically, a significantly reduced survival associated with undergoing PCI instead of CABG. 6, 7 The SYNTAX trial compared outcomes in 1800 patients with left main or three-vessel CAD randomized to PCI with a drug-eluting stent (DES) vs. CABG. In addition, the investigators prospectively attempted to clarify the CABG vs. PCI decision-making process by (i) standardizing the measurement of CAD complexity using an angiographic score (SYNTAX score); and (ii) incorporating CAD complexity with prognostic clinical factors into a broader mortalitypredicting score (SYNTAX score II), to be used for individualized decision-making regarding revascularization strategy (http://www.syn taxscore.com/). Overall SYNTAX found PCI to be associated with increased death/MI/stroke/repeat revascularization compared with CABG in high SYNTAX score but not low SYNTAX score patients. Although the diabetes subgroup was underpowered (450 subjects), the death/MI/stroke findings were consistent with the rest of the trial, and PCI was accepted as a 'reasonable alternative' to CABG for diabetic patients with lower complexity multivessel CAD. 7, 8 However, these results were not supported by the larger FREEDOM trial, whose 1900 diabetic subjects with multivessel CAD randomized to CABG vs. PCI experienced more death/MI/stroke with PCI as compared with CABG across all SYNTAX scores (treatment effect for subgroup interaction, P = 0.58).
In this issue of the journal, the SYNTAX investigators have attempted to address the possibility of a Type II error by pooling patient-level data from three CABG vs. DES PCI randomized controlled trials (SYNTAX, PRECOMBAT, and BEST). 9 Of the 1068 patients with diabetes, PCI-treated patients with the lowest SYNTAX scores (<32), while requiring more repeat revascularization when treated with PCI, had similar cardiac death/MI/stroke events to those treated by CABG. In addition, the authors validated the SYNTAX II score, developed in the original SYNTAX cohort, in the pooled PRECOMBAT and BEST cohorts, showing it to have good calibration for the prediction of mortality, and similar, moderate discriminatory ability for diabetic and non-diabetic subjects alike (C-indices of 0.68 and 0.67, respectively). The strengths of this study include its median 5-year follow-up. FREEDOM had a median follow-up of only 3.8 years. Longer followup is extremely relevant to patients contemplating coronary revascularization, with the average life expectancies often exceeding 20 years. Another strength is the blinded, core lab-measured SYNTAX score. The SYNTAX score has been shown to be strongly reproducible among trained technicians. 10 The protocol by which SYNTAX scores were calculated in FREEDOM has not been specifically published. However, it should be noted that calculation of the angiographic SYNTAX score requires training and careful attention. Large and clinically significant variability between physician grading as well as discrepancies between on-site vs. core lab grading have been reported. 10, 11 A major weakness of the present study is its heterogeneity in many respects. The population of complex CAD patients included left main and multivessel disease patients. SYNTAX score in patients with identical atherosclerosis burdens can be >10 points greater when the plaque is in the left main as compared with other locations. Precise SYNTAX score cut-offs should be derived separately for left main and multivessel disease populations. In this study, the authors confirm their findings in the multivessel population, but the left main population is notably small (366 subjects). Ideally, the SYNTAX score levels associated with PCI safety will be determined through a combined, patient-level analysis of SYNTAX, FREEDOM, BEST, and FAME III trials for multivessel disease patients, and the SYNTAX, PRECOMBAT, EXCEL, and NOBLE trials for left main disease patients. Heterogeneity in the patient populations (Asian vs. European), in the core labs, and in the study inclusion criteria could also affect the findings.
The SYNTAX score II, while shown to have moderate discriminatory value, still can serve as an objective, unbiased guide to the revascularization strategy to be taken into account by the Heart Team. Of course, individual patient factors, unaccounted for in the SYNTAX score II, ranging from co-morbidities to technical risks to social issues, also need to be considered (Figure 1) .
In summary, with this study, the SYNTAX score, as an 'objective' measure of CAD complexity, grows stronger, having long surpassed the older one-, two-, and three-vessel disease characterization of CAD. It serves as a useful tool in terms of communicating the severity of disease and, with studies like this one, understanding its prognostic implications. The ability of the SYNTAX score II to 'weight' CAD complexity (SYNTAX score) with important clinical characteristics to help predict individual patient outcomes should be useful in improving the 'CABG vs. PCI' decision-making. This study shows that this seems to hold true even in patients with diabetes, where the stakes are highest.
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